JOYSBIO's SARS-COV-2 Antigen Rapid test detects OMICRON variant
PR93329
TIANJIN, China, Nov. 30, 2021 /PRNewswire=KYODO JBN/ --
- JOYSBIO, one of the world's leading manufacturers of COVID-19 tests,
announces their tests are available everywhere and identifies new, dangerous
variants.
JOYSBIO, one of the world's leading manufacturers of lateral flow rapid tests,
is proud to announce that their tests are available around the world.
Furthermore, they've been able to show that their test can detect the new
Omicron (B.1.1.529). This variant was the subject of a recent emergency WHO
meeting and is the cause of many countries instituting travel bans.
The JOYSBIO SARS-COV-2 Antigen Rapid Test Kit is able to detect SARS-COV-2
variants including B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), P.1
(Gamma), and B.1.1.529 (Omicron). More information is available at
https://en.joysbio.com/covid-19-antigen-rapid-test-kit/.
"The Omicron variant is still a bit of a mystery. It appears to be more easily
transmissible," said Rick Zhang, Business Development Director for JOYSBIO.
"According to the sequencing data of the new variant, the target protein domain
of our test kit is unaffected. Therefore, the SARS-COV-2 antigen rapid test
kits produced by JOYSBIO are able to detect the Omicron variant."
The report from the WHO, only a few days old, contains some troubling
indications. "This variant has a large number of mutations, some of which are
concerning. Preliminary evidence suggests an increased risk of reinfection with
this variant, as compared to other VOCs.
"Individuals are reminded to take measures to reduce their risk of COVID-19,
including proven public health and social measures such as wearing well-fitting
masks, hand hygiene, physical distancing, improving ventilation of indoor
spaces, avoiding crowded spaces, and getting vaccinated." -
https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
The JOYSBIO COVID-19 Antigen Rapid Test Kit delivers results in just 15 minutes.
The JOYSBIO test is extremely accurate. "According to the clinical analysis of
492 samples, the detection sensitivity is 98.13%, and the specificity is
99.22%." (https://en.joysbio.com/covid-19-antigen-rapid-test-kit/) It has been
used and tested against SARS-COV-2 variants and has shown itself to be just as
responsive, accurate, and rapid.
"At JOYSBIO," Zhang said. "We're committed to keeping up with all the variants
of SARS-COV-2. We will continue to improve our existing tests and develop new
ones as needed. The sooner one knows that they're ill, the sooner they can take
proactive steps to prevent spread and take care of oneself."
Zhang went on to say that protecting lives is the JOYSBIO mission, every day.
More information is available at
https://en.joysbio.com/covid-19-antigen-rapid-test-kit/.
About JOYSBIO
JOYSBIO (Tianjin) Biotechnology Co., Ltd. is an R&D-focused Chinese
biotechnology company that develops, manufactures, and supplies high-quality
medical in-vitro diagnostic (IVD) rapid test kits as well as revolutionary
customized reagent kits to all parts of the world. JOYSBIO was founded by a
team of professionals with many years of combined technical, marketing/sales,
operational and manufacturing expertise in this industry.
SOURCE: JOYSBIO (Tianjin) Biotechnology Co., Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。